Compare AbCellera Biologics Inc (ABCL) vs IAC/Interactivecorp (PPLI) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

PPLI trades at $47.62, up 1.86% today, showing bullish technical momentum with moving averages supporting the uptrend. However, the stock has missed earnings expectations for three consecutive quarters, with Q1 2026 EPS of -$0.94 falling short of the -$0.37 estimate. Despite a high gross margin of 66.49%, net income margin remains thin at 1.75%, and cash flow turned negative in 2025 with a net outflow of $820.42 million. Analyst consensus remains positive with a $55.40 price target, though recent news questions valuation after a rally.

The outlook is mixed: strong analyst buy ratings and a discounted P/B of 0.77 suggest upside potential, but persistent earnings misses and negative cash flow pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges. Investors should weigh the bullish technical setup against fundamental weaknesses and high debt levels before committing capital.